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Abstract
Rationale Pharmacological stimulation of D2 receptors modu-
lates prefrontal neural activity associatedwith workingmemory
(WM) processing. The Tallele of a functional single-nucleotide
polymorphism (SNP) withinDRD2 (rs1076560 G > T) predicts
reduced relative expression of the D2S receptor isoform and
less efficient neural cortical responses during WM tasks.
Objective We used functional MRI to test the hypothesis that
DRD2 rs1076560 genotype interacts with pharmacological
stimulation of D2 receptors with bromocriptine on prefrontal
responses during different loads of a spatial WM task (N-Back).
Methods Fifty-three healthy subjects (38 GG and 15 GT)
underwent two 3-T functional MRI scans while performing
the 1-, 2- and 3-Back versions of the N-BackWM task. Before
the imaging sessions, either bromocriptine or placebo was
administered to all subjects in a counterbalanced order. A
factorial repeated-measures ANOVA within SPM8 (p<0.05,
family-wise error corrected) was used.
Results On bromocriptine, GG subjects had reduced prefron-
tal activity at 3-Back together with a significant decrement in
performance, compared with placebo. On the other hand, GT
subjects had lower activity for the same level of performance
at 1-Back but a trend for reduced behavioral performance in
the face of unchanged activity at 2-Back.
Conclusions These results indicate that bromocriptine stimu-
lation modulates prefrontal activity in terms of disengagement
or of efficiency depending on DRD2 genotype and working
memory load.
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Working memory (WM) refers to the ability to maintain,
manipulate and access mental representations as needed to
support complex cognition (Baddeley 1992). Single-cell re-
cording studies in nonhuman primates and functional neuro-
imaging studies in humans support the critical involvement of
the prefrontal cortex (PFC) in WM (Goldman-Rakic 1999;
Callicott et al. 1999; Barbas 2000; Passingham and Sakai
2004). Prefrontal neuronal activity during performance of
WM tasks is modulated by dopamine (Bertolino et al. 2006;
Tan et al. 2007). More specifically, dopamine directly regu-
lates firing of pyramidal neurons and of their GABA inhibi-
tory surround within PFC to focus neuronal resources to the
task at hand (Seamans and Yang 2004). The relationship
between dopamine levels and neuronal activity describes a
nonlinear function (inverted-U) (Seamans and Yang 2004). In
other words, there is a critical range of dopamine stimulation
within which task-related activity is more focused while task-
unrelated activity is attenuated, i.e. more efficient neuronal
activity for better behavioral performance (Mattay et al. 2003).
Above or below this critical range of dopamine stimulation,
behavioral performance is deteriorated and the balance be-
tween task-related and task-unrelated neuronal activity varies
engendering globally attenuated or excessive PFC activity
(Mattay et al. 2003). Several studies in nonhuman primates
and in humans have demonstrated that this relationship is
strongly modulated by dopamine D1 receptors (Sawaguchi
and Goldman-Rakic 1991; Seamans and Yang 2004;
Takahashi et al. 2008). However, other single-cell recording
studies in nonhuman primates have also demonstrated that
dopamine D2 receptors selectively modulate prefrontal neural
activity associated with memory-guided responses during
spatial WM (Wang et al. 2004). Further behavioral experi-
ments in humans have indicated that systemic administration
of D2 receptor agonists like bromocriptine or antagonists like
haloperidol and sulpiride is respectively associated with rela-
tive improvement or deterioration of spatial WM performance
(Luciana et al. 1992; Luciana and Collins 1997; Kimberg et al.
2001; Mehta et al. 2003, 2004; Fischer et al. 2010). Several
studies have also reported that the drug-induced effects on
cognitive tests are correlated with individual differences in
WM capacity, often measured with the listening span task
(Daneman and Carpenter 1980; Kimberg et al. 1997; Mehta
and Riedel 2006; Frank and O'Reilly 2006). Previous results
indicate that performance during cognitive tasks is improved
by D2 agonists in subjects with lower WM capacity and
impaired in subjects with higher WM capacity (Kimberg
et al. 1997). These findings have been accounted for by the
inverted-U-shaped dose–response curve model, i.e. D2 ago-
nists might stimulate the dopamine system to ‘optimal’ or to
overdosed levels in individuals with low vs high baseline
dopamine system functioning (Meyer-Lindenberg and
Weinberger 2006). Consistent with the behavioral experi-
ments, several studies with functional imaging have reported
that bromocriptine administration is beneficial for prefrontal
activity in subjects with lower capacity, whereas it is detri-
mental in subjects with higher WM capacity (Gibbs and
D'Esposito 2005a, b). All these results together suggest that
improvement or deterioration of behavioral performance and
cortical activity from manipulation of D2 signaling is associ-
ated with the individual, possibly genetic, makeup of individ-
uals. This hypothesis has been supported by several recent
studies investigating the relationship between genetic varia-
tion within DRD2 and pharmacological D2 receptor stimula-
tion in different cognitive domains (Kirsch et al. 2006; Cohen
et al. 2007).
D2 receptors exist in two alternatively spliced isoforms, the
D2 long (D2L) which is mainly post-synaptic and the D2 short
(D2S) which has predominant presynaptic autoreceptor func-
tions (Khan et al. 1998; Usiello et al. 2000). Earlier studies
suggest association between an intronic polymorphism
(rs1076560, G > T) and relative expression of these two iso-
forms: subjects carrying the minor (T) allele have reduced
relative prefrontal and striatal expression of D2S (Zhang et al.
2007) and less efficient neural cortical and subcortical re-
sponses during performance of the 2-Back WM task compared
with GG subjects (Zhang et al. 2007; Bertolino et al. 2009a, b,
2010). More specifically, the differences between the two ge-
notypes emerged at the 2-Back working memory condition,
whereas no such difference was found at 1-Back. These results
suggested that the 2-Back condition was within the working
memory capacity range of GG subjects but exceeded that of GT
subjects (Zhang et al. 2007).
In the present double-blind, crossover, randomized, placebo-
controlled study in healthy subjects, we examined whether
DRD2 rs1076560 predicts prefrontal responses to pharmaco-
logical stimulation of D2 receptors with bromocriptine during a
spatial WM task. Based on our earlier studies, we increased the
range of working memory load by also using a 3-Back working
memory condition so as to evaluate the interaction between
drug, genotype and working memory load presumably both
within and beyond working memory capacity for both geno-
type groups. Based on our earlier studies, we hypothesized that
the effects of bromocriptine on prefrontal behavior and activity
would be genotype- and load-dependent.
Materials and methods
Subjects
Fifty-three healthy subjects (24 males, mean age ± SD 27.2±
4.4 years) entered the study. All subjects were Caucasians
from the region of Puglia in Italy. Inclusion criteria were
absence of any psychiatric disorder, as evaluated with the
2362 Psychopharmacology (2014) 231:2361–2370
Structured Clinical Interview for Diagnostic and Statistical
Manual of Mental Disorders IV; of any significant neurolo-
gical or medical condition revealed by clinical and magnetic
resonance imaging evaluation; of history of head trauma with
loss of consciousness; and of pharmacological treatment or
drug abuse in the past year. The Wechsler Adult Intelligence
Scale—Revised was used to evaluate intelligence quotient
(IQ), the Hollingshead Scale (Hollingshead and Redlich
1958) to calculate the socioeconomical status and the Edin-
burgh Inventory (Oldfield 1971) to measure handedness.
The present experimental protocol was approved by the
local institutional review board. After complete description of
the study to the subjects, written informed consent was
obtained.
Experimental procedure
Each subject underwent a very well-established protocol
which makes use of systemic administration of bromocriptine
to stimulate D2 receptors (Luciana et al. 1998; Mehta et al.
2001; Gibbs and D'Esposito 2005a, b; Kirsch et al. 2006;
Cools et al. 2007, 2009; vanHolstein et al. 2011). Each subject
was tested twice, once after administration of 1.25 mg bromo-
criptine and once after placebo (lactose), in a randomized,
double-blind, crossover design counterbalanced for the order
of drug administration. Both bromocriptine and placebo were
administered orally in identical capsules together with 10 mg
domperidone, a peripheral dopaminergic antagonist which
does not pass the blood–brain barrier, to reduce possible side
effects, like nausea, vomiting and dizziness known to be
induced by bromocriptine intake. The dose of 1.25 mg was
carefully chosen as it has previously been reported to modu-
late spatial short-term memory without producing appreciable
adverse effects, unlike the higher dose of 2.5 mg (Luciana
et al. 1998; Mehta et al. 2001; Gibbs and D'Esposito 2005a, b;
Kirsch et al. 2006; Cools et al. 2007, 2009; van Holstein et al.
2011). The participants were not able to differentiate bromo-
criptine from placebo. The two functional MRI (fMRI) ses-
sions, separated by 2 weeks, occurred approximately 150 min
after administration of bromocriptine or of placebo, since the
range of peak effectiveness for bromocriptine was estimated
from previous studies to occur between 90 and 180 min after
pill ingestion (Luciana et al. 1992; Luciana and Collins 1997;
Kimberg et al. 1997, 2001; Mehta et al. 2001; Gibbs and
D'Esposito 2005a, b; Kirsch et al. 2006; Cools et al. 2007).
A blood sample was obtained immediately before and at the
end of the fMRI session to test blood prolactin levels. This
procedure was performed with the objective of evaluating in
each individual that bromocriptine had caused the known
reduction of prolactin over and beyond those correlated with
circadian rhythm and the stress induced by the fMRI
procedure.
Genotype determination
Subjects were genotyped for DRD2 rs1076560. This
single-nucleotide polymorphism (SNP) was analysed in
our laboratory with allele-specific PCR primers as de-
scribed previously (Zhang et al. 2007; Bertolino et al.
2009a, b). Thirty-eight subjects were GG and 15 were
GT. None of the subjects were homozygous for the T
allele, consistent with previous studies (Zhang et al.
2007). Allelic distribution of this genetic variant in our
sample was in Handy–Weinberg equilibrium ( 2=1.44,
p=0.23), and it was consistent with the known distribution
of these two alleles in the Caucasian population (http://
www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=
1076560), indicating that our distribution of genotypes is
representative of the general population.
N-Back working memory paradigm
During fMRI, all subjects completed a blocked para-
digm of the N-Back task. Briefly, ‘N-back’ refers to
how far back in the sequence of stimuli the subject
had to recall. The stimuli consisted of numbers (1–4)
shown in a random sequence and displayed at the points
of a diamond-shaped box, and in WM conditions, the
task required recollection of a stimulus seen one, two or
three stimuli previously (1-, 2- or 3- Back, respectively)
while subjects continued to encode additionally incom-
ing stimuli. There was also a non-memory-guided con-
trol condition (0-Back) that simply required subjects to
identify the stimulus currently seen. Three different task
runs were used, each alternating four 30-s blocks of a
0-Back condition with four 30-s blocks of a WM con-
dition (1-, 2- or 3-Back, respectively). Each run lasted
4 min and 8 s. Stimuli were presented via a back-
projection system, and behavioral responses were re-
corded through a fiber optic response box which
allowed measurement of accuracy and reaction time for
each trial. All subjects were trained on the task before
the fMRI session.
Demographic, clinical and behavioral data analysis
ANOVAs and 2 were used to assess potential differences
between the two DRD2 genotype groups for all demographic
variables and to assess the effect of bromocriptine vs placebo
on blood levels of prolactin. Behavioral data (accuracy
and reaction time at 1-, 2- and 3-Back) were compared
using repeated-measures factorial ANOVA with genotype
as between-subjects factor and load and drug as repeated-
measures factors. A dependent-sample t test was used for
post hoc analysis on behavioral data within each genotype
group.





Blood oxygen level-dependent (BOLD) fMRI was performed
on a GE Signa 3-T scanner (General Electric, Milwaukee,
WI), equipped with a standard quadrature head coil. A
gradient-echo planar imaging sequence (repetition time,
2,000 ms; echo time, 28 ms; 20 interleaved axial slices;
thickness, 4 mm; gap, 1 mm; voxel size, 3.75×3.75×5; flip
angle, 90°; field of view, 24 cm; matrix, 64×64) was used to
acquire 120 volumes for each task run. The first four scans
were discarded to allow for a T1 equilibration effect.
fMRI data analysis
Analysis of the fMRI data was completed using Statistical
Parametric Mapping (SPM8, http://www.fil.ion.ucl.ac.uk/
spm). Images, for each subject, were realigned to the first
volume in the time series, and movement parameters were
extracted to exclude subjects with excessive head motion
(>2 mm of translation, >2° rotation). Images were then re-
sampled to a 3.75-mm isotropic voxel size, spatially normali-
zed into a standard stereotactic space (Montreal Neurological
Institute, MNI, template) and smoothed using a 10-mm full-
width half-maximum isotropic Gaussian kernel to minimize
noise and to account for residual inter-subject differences. A
box car model convolved with the haemodynamic response
function (HRF) at each voxel was modeled. Subject-specific
movement parameters, obtained from the realignment proce-
dure, were included in the general linear model (GLM) as
covariates, taking into account the effect of subject motion. In
the first-level analysis, linear contrasts were computed pro-
ducing a t statistical map at each voxel for the 1-, 2- and 3-
Back conditions, assuming the 0-Back condition as a baseline.
All individual contrast images were entered in a second-level
random-effects analysis. A factorial ANOVA was then per-
formed, with load and drug as repeated-measures factors and
DRD2 rs1076560 genotype as the between-subjects factor.
Furthermore, t test for dependent or independent samples as
appropriate outside of SPM was used for post hoc compari-
sons. We used a statistical threshold of p<0.005 (minimum
cluster size [k]=3), with further family-wise error correction at
p<0.05, using as volume of interest theWake Forest University
PickAtlas (http://fmri.wfubmc.edu/cms/software#PickAtlas)
Brodmann's area 9 (BA9). This region of interest (ROI) inclu-
ded 193 voxels. This region was chosen a priori based on our
earlier studies (Zhang et al. 2007; Bertolino et al. 2009a, b;
Fazio et al. 2011) and because of our strong hypothesis on D2
modulation of dorsolateral prefrontal cortical activity. Outside
the ROI, no activation encompasses the threshold of family-
wise error (FWE) p<0.05 whole-brain correction.
BOLD responses were extracted from significant clusters
using MarsBaR (http://marsbar.sourceforge.net/). Finally, to
explore the relationship between behavior and BOLD
responses in the PFC region showing a genotype by WM
load by drug interaction (see ‘Results’), we used linear
regression analyses within SPM entering the single-subject
contrasts and accuracy as variables. This analysis was per-
formed separately for the two genotype groups and for all
conditions (i.e.WM loads and drug). Specific Tcontrasts were
built in order to investigate correlations between accuracy and
prefrontal activity. These analyses were corrected with the
same algorithm described for the factorial ANOVA and using
the same prefrontal ROI (see above).
Results
Demographic data
ANOVAs and 2 tests indicated that there were no significant
differences between genotype groups in any demographic
variable (all p>0.1) (Table 1).
Prolactin reduction
ANOVA in the whole sample of subjects demonstrated that
bromocriptine decreased plasma levels of prolactin relative to
placebo (F(1,51)=28.8, p<0.001). There was no main effect of
genotype or any interaction between genotype and drug (all
p>0.3).
Behavioral data
A repeated-measures ANOVA of accuracy data indicated a
main effect of load (F(2,102)=41.58, p=0.0001; increasing
WM load was associated with declining accuracy), no main
effect of DRD2 genotype (F(1,51)=0.23, p=0.63), no main
effect of drug (F(1,51)=0.60, p=0.43), no significant drug by
genotype interaction (F(1,51)=0.005, p=0.94) and a significant
interaction between WM load, DRD2 genotype and drug
(F(2,102) =8.2, p=0.0004) (Fig. 1). Post hoc analysis
Table 1 Demographics of the subjects included in the study
DRD2 (total N) p value
GG (38) GT (15)
Gender (males) 15 9 0.17
Age (years) 27.5 (±5) 26.4 (±2.5) 0.44
IQ (WAIS-R) 111.5 (±13.7) 110.7 (±15.2) 0.87
Socioeconomic status
(Hollingshead Scale)
44.9 (±14.8) 48.1 (±15.8) 0.5
Handedness (Edinburgh
Inventory)
0.7 (±0.3) 0.6 (±0.5) 0.41
IQ intelligence quotient, WAIS-R Wechsler Adult Intelligence Scale—
Revised
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χ
demonstrated that after bromocriptine administration, GG
subjects had reduced WM performance at 3-Back compared
with placebo (p=0.002), while GT subjects tended to have
reduced performance at 2-Back compared with placebo (p=
0.07). All other post hoc comparisons were not statistically
significant (all p>0.1). Thus, in line with a previous study
(Markett et al. 2009), individual differences in WM capacity
were only present at a greater WM load.
No statistically significant main effects or interactions were
present on reaction time data (all p>0.5).
BOLD response
We evaluated associations of DRD2 genotype and D2 stimula-
tion with brain activity during WM using a parametric N-back
working memory task involving increasing cognitive load (1-,
2- and 3-Back). ANOVA demonstrated a strong main effect of
load in the whole WM network, including the left inferior
frontal gyrus (BA9 x=−48, y=16, z=25, F(2,306)=18.65, k=87,
Z=5.47, FWE p<0.001) where BOLD responses increased
linearly from 1- to 2- and 3-Back (3-Back >1-Back:
p<0.0001, 3-Back >2-Back: p=0.008, 2-Back >1-Back: p=
0.04) (Fig. 2). Consistent with previous studies (Zhang et al.
2007; Bertolino et al. 2009a, b; Fazio et al. 2011), the results
also demonstrated a main effect of genotype in the left superior
frontal gyrus (BA9 x=−33, y=49, z=40, F(1,306)=18.28, k=15,
Z=4.05, FWE p=0.003) where GTsubjects have a significantly
greater activity compared with GG subjects (Fig. 3). No inter-
actions of genotype by WM load, of genotype by drug and of
WM load by drug were found (all p>0.05). Finally, ANOVA
demonstrated an interaction between WM load, DRD2 geno-
type and drug in the left superior frontal gyrus (BA9 x=−33, y=
46, z=32,F(2,306)=6.54, k=14,Z=2.94, FWEp=0.04) (Table 2).
BOLD responses extracted from this cluster revealed the fol-
lowing: GG subjects on placebo increase prefrontal activity
from 1- or 2- to 3-Back (3-Back >1-Back: p=0.0008, 3-Back
> 2-Back: p=0.003, 2-Back vs 1-Back: p=0.49), whereas on
bromocriptine, this pattern was attenuated, especially from 2- to
3-Back (3-Back >1-Back: p=0.07, 3-Back vs 2-Back: p=0.98,
2-Back > 1-Back: p=0.08). Moreover, GG subjects after bro-
mocriptine have decreased BOLD responses at 3-Back com-
pared with placebo (p=0.02). On the other hand, the pattern of
BOLD responses in GT subjects was different across the two
sessions. When on placebo, there was no significant difference
between the threeWM loads (all p>0.35). After bromocriptine,
GTsubjects have amore physiological pattern of activity which
tended to increase linearly from 1- to 2- and 3-Back (3-Back >
1-Back: p=0.01, 3-Back >2-Back: p=0.02, 2-Back >1-Back:
0.09). Moreover, in GT subjects, bromocriptine is associated
with decreased BOLD responses at 1-Back compared with
placebo (p=0.009) (Fig. 4a, b).
Fig. 2 Rendered image of the brain showing the network activated
during N-Back task. The color bar represents t values
Fig. 3 Rendered image of the brain showing the cluster in the left
superior frontal gyrus where a main effect of DRD2 genotype was found
(GT > GG, see text for statistics). The color bar represents t values
Fig. 1 Behavioral data. Bar graph (mean ± SE) of working memory
accuracy. An interaction between WM load, DRD2 genotype and drug
was found (GG subjects have a significant decrement of accuracy at 3-
Back on bromocriptine; GT subjects have a trend for reduced perfor-
mance at 2-Back on bromocriptine; see text for statistics)
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In order to explore the potential for changes in BOLD
response identified in the interaction to correlate with measu-
rable behavioral differences, we performed a linear regression
in SPM. This analysis indicated in GG subjects on bromocrip-
tine a statistical trend for a positive correlation between BOLD
responses in the left superior frontal gyrus (BA9) and accura-
cy at 3-Back (x=−44, y=8, z=40, t(1,36) = 3.07, k=4, FWE p=
0.08). On the other hand, in GTsubjects on bromocriptine, we
found a negative correlation between BOLD responses in
BA9 and accuracy at 2-Back (x=−48, y=16, z=40, t(1,13)=
4.97, k=16, FWE p=0.006) (Fig. 5a, b).
Discussion
The present results demonstrate an interaction between bro-
mocriptine stimulation, DRD2 rs1076560 genotype and WM
load on prefrontal behavior and activity. This study adds to a
growing body of research demonstrating that the effects of
dopamine drugs on brain activity and performance are modu-
lated by genetic variables that might also index baseline
dopamine levels (Mattay et al. 2003; Frank and O'Reilly
2006; Kirsch et al. 2006; Meyer-Lindenberg and Weinberger
2006; Cools et al. 2007). In particular, the present results
reveal that bromocriptine stimulation interacts with DRD2
genotype in modulating load-related prefrontal activity during
WM processing. More specifically, bromocriptine stimulation
in GG subjects attenuates a load-related linear increase of
prefrontal activity which is present when they are on placebo.
Moreover, on bromocriptine, prefrontal BOLD signal of GG
subjects decreased at the higher WM load together with a
significant decrement in performance (accuracy). A possible
interpretation of these results is that these subjects reduce
engagement of prefrontal resources to the task, because their
capacity of WM is exceeded at 3-Back. Consistent with this
interpretation, regression analysis revealed a statistical trend
for a positive relationship between prefrontal activity and
accuracy at 3-Back on bromocriptine (lower activity for worse
performance). In GT subjects, we found a reduction in BOLD
signal at 1-Back after bromocriptine compared with placebo
for the same level of performance, suggesting that they had
increased efficiency. However, in this genotype configuration,
stimulation with bromocriptine is associated with a linear
increase in prefrontal activity as the task becomes more
Table 2 Statistics and Montreal Neurological Institute coordinates for the effects of load and DRD2 genotype as well as for interaction between drug,
genotype and load on brain activity during N-Back task
Brain region BA MNI coordinates F k Z FWE p
x y z
Main effect of WM load Left inferior frontal gyrus BA9 −48 16 25 18.65 87 5.47 0.0001
Main effect of DRD2 Left superior frontal gyrus BA9 −33 49 40 18.28 15 4.05 0.003
Drug by genotype by WM load interaction Left superior frontal gyrus BA9 −33 46 32 6.54 14 2.94 0.04
WMworking memory, BABrodmann's area, MNIMontreal Neurological Institute, FWE family-wise error
Fig. 4 aRendered image showing the cluster in the left superior frontal
gyrus where a three-way interaction between WM load, DRD2 genotype
and treatment was found. The color bar represents F values. bBar graph
(mean ± SE) of BOLD responses extracted from the cluster depicted in a.
GG subjects have a significant reduction of activity at 3-Back on bromo-
criptine, while GT subjects have reduced activity at 1-Back on bromo-
criptine. See text for statistics
2366 Psychopharmacology (2014) 231:2361–2370
difficult, with a trend for reduced behavioral performance
already at 2-Back, suggesting greater effort for worse task
performance. Consistently, we found a negative relationship
between prefrontal activity of GT subjects and accuracy at 2-
Back on bromocriptine. These results are consistent with other
studies demonstrating that genetically determined D2 receptor
levels are crucial to modulate cognition (Jocham et al. 2009;
Markett et al. 2009).
A possible biological mechanism underlying the present
results may be that the effect of bromocriptine on cortical
activity is associated with its preferential presynaptic action
and with the differential expression ratios of D2 isoforms in
GG and GT subjects. Evidence from the animal literature
suggests that low doses of D2 agonists actually exert their
effects primarily via presynaptic mechanisms (Richfield et al.
1989; Usiello et al. 2000; Tamminga 2002; Tamminga and
Carlsson 2002; Frank and O'Reilly 2006; Cools et al. 2009;
Anzalone et al. 2012). Presynaptic D2 autoreceptors tightly
control the level of dopamine release via an inhibitory feed-
back (Starke et al. 1989; Grace 1995; Schmitz et al. 2003).
Thus, D2 agonists like bromocriptine stimulate presynaptic
D2 autoreceptors and reduce dopamine release. Moreover,
earlier studies have demonstrated that GG subjects have a
relatively greater expression of D2S (Zhang et al. 2007) and
are generally more efficient at 2-Back, presumably because
their dopamine levels are within a hypothetical optimal range
predicted by the inverted-U-shaped dose–response curve
(Williams and Goldman-Rakic 1995). Consistent with this
earlier literature, GG subjects reveal a reduction in terms of
both accuracy and cortical activity only at the greater load (3-
Fig. 5 a3-D rendering of the negative correlation between prefrontal activity and accuracy at 2-Back in GT subjects on bromocriptine with the relative
scatterplot showing individual data points (b). The color bar represents t values. See text for statistics
Fig. 6 Hypothetical inverted-U model describing the effects of DRD2
genotype and bromocriptine on prefrontal dopamine signaling and function.
During placebo, GG subjects are located near the peak of the D2-response
curve, i.e. optimal signaling and prefrontal function. Instead,GTsubjects have
greater dopamine signaling and less optimal prefrontal function. Administra-
tion of bromocriptine in GG subjects may shift D2 signaling to suboptimal
levels and lower prefrontal efficiency at high WM load. On the other hand,
administration of bromocriptine in GT subjects may shift D2 signaling to
more optimal levels, thus improving prefrontal function of GT individuals at
low levels of working memory load (1-Back). However, this mechanism is
not sufficient to increase prefrontal efficiency in GT subjects at greater levels
of working memory loads (2-Back)
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Back) after bromocriptine stimulation. This effect is presu-
mably because their dopamine levels are shifted below the
optimal range by bromocriptine. Conversely, in GT subjects
who have relatively lower levels of D2S and who are physio-
logically less efficient to begin with (Zhang et al. 2007),
bromocriptine stimulation of presynaptic D2 receptors re-
duces the supra-normal levels of dopamine (Bertolino et al.
2010), improving their efficiency at 1-Back, only. On the other
hand, this mechanism would not be sufficient to improve their
efficiency at 2-Back, which is actually reduced probably
because of their more physiologically limited WM capacity
(Zhang et al. 2007; Bertolino et al. 2009a, 2010) (Fig. 6). This
hypothetical interpretation is supported by studies in humans,
suggesting that the effects of dopamine D2 agonists and
antagonists on cognition and prefrontal activity are correlated
with the baseline levels of dopamine and with capacity limi-
tations (Kimberg et al. 1997; Frank and O'Reilly 2006; Kirsch
et al. 2006; Cohen et al. 2007, 2009; van Holstein et al. 2011).
In particular, consistent with our interpretation, Frank and
O'Reilly (2006) and Cools et al. (2009) demonstrated that
low doses of D2 agonist impaired cognitive performance in
subjects with high baseline levels of dopamine, presumably as
a result of reduced dopamine bursts. Of note, our results are
apparently at odds with earlier studies reporting improvement
of cognitive performance in subjects with a lower WM capa-
city (Kimberg et al. 1997; Gibbs and D'Esposito 2005a, b).
However, it is important to mention that our subjects had on
average high WM performance (2-Back, mean ± SD 85.25±
15.48 %; 3-Back, mean ± SD 74.45±21.09 %) as compared
with earlier studies with the same task (Mattay et al. 2003: 2-
Back, mean ≈84 %; 3-Back, mean ≈65 %; Goldberg et al.
2003: 2-Back, mean ≈78 %), suggesting that there may be a
ceiling effect. This interpretation also has another corollary.
Earlier studies with this task have reported that activity in PFC
is reduced at 3-Back compared with 2-Back, suggesting a
nonlinear relationship between cognitive demand and prefron-
tal activity (Callicott et al. 1999). Here, we found that PFC
activity is positively related with WM demands, such that
activity increases linearly with greater memory loads. These
results are consistent with the interpretation above detailed
because it is possible that in our subjects, the cognitive de-
mands elicited by the 3-Back did not breach average WM
capacity, resulting in increased activity.
Some potential limitations of the present data have to be
discussed. First, the inclusion of women may introduce addi-
tional variance in the data because the dopamine system is
modulated by the menstrual cycle (Dreher et al. 2007). Al-
though we did not collect menstrual cycle position informa-
tion, it is likely that this variable would have been randomly
distributed across all conditions and, therefore, would not
have affected the results in any reliable way. Second, in this
study, we used a block design paradigm in which the demand
for executive processes involves information updating and
temporal indexing increases concurrently with maintenance
and retrieval demands. Earlier studies have demonstrated that
the effects of bromocriptine are associated with specific
phases of WM processing (Gibbs and D'Esposito 2005a, b;
Cools and D'Esposito 2011). Since our task does not allow
separation of updating and maintenance, we cannot disentan-
gle potential effects of the drug or the gene on these WM
components.
In conclusion, our study in healthy subjects indicates that
genetic variation in DRD2modulating D2 presynaptic signa-
ling is relevant to modulate specific aspects of physiology
during cognitive processing. Additional studies not only with
dopamine D2 agonist but also with antagonist are needed to
elucidate the mechanisms of the effect ofDRD2 rs1076560 on
WM processes.
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